AGP Limited
PPSX:AGP157.11
PKR
-3.83
(-2.38%)
AGP Limited
PSX:AGP
(Pakistan Stock Exchange)
Recent
price
157.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AGP Limited is a Pakistan-based pharmaceutical company engaged in the research, manufacturing, marketing, distribution, and export of branded generic pharmaceutical formulations, licensed original therapeutics, and consumer healthcare products. Founded in 1989 and headquartered in Karachi, Pakistan, the company operates as a key operating entity of the OBS Group. AGP Limited serves retail pharmacies, private healthcare institutions, governmental agencies, and medical specialists across domestic and export markets, maintaining an international commercial presence across Central Asia, Southeast Asia, and Africa. The company develops and commercializes prescription drugs, hospital care solutions, and over-the-counter wellness products organized into systematic therapeutic categories: anti-infectives and broad-spectrum antibiotics, including Ceclor, Keflex, and Nebcin; analgesics, antispasmodics, and anti-inflammatory agents, including Anafortan and Spasfon; respiratory medications and anti-allergic formulations, including Rigix; gastroenterology and hepatobiliary therapies, including Hepa-Merz and various gastrointestinal treatments; cardiovascular, endocrine, and metabolic disease therapies, including antihypertensives, statins, and oral anti-diabetics; bone health, pediatric supplements, and nutraceuticals, including Osnate-D; and specialized institutional therapeutics. Beyond proprietary manufacturing, AGP Limited provides toll manufacturing, contract manufacturing, regulatory licensing, and third-party commercialization services for multinational pharmaceutical originators. In recent operational and strategic developments, AGP Limited expanded its market capitalization and therapeutic footprint through the landmark acquisition of a select portfolio of mature, established commercial brands and related assets from Viatris Inc. (formerly Mylan and Upjohn), significantly enhancing its market share in cardiovascular, central nervous system, and pain management segments. The company has also expanded its manufacturing infrastructure through facility upgrades compliant with international Current Good Manufacturing Practice (cGMP) standards, broadened its nutraceutical product pipeline, and deepened strategic partnerships with global pharmaceutical licensors to introduce advanced specialty medications and biosimilars.